title: Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
abstract: BACKGROUND
  To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC).
  
  
  METHODS
  A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed.
  
  
  RESULTS
  Of 277 patients (median age: 58years), the majority had Stage III and IV (86%) disease, and 72% had serous histology. 244 (88%) were treated with C+Bev and 33 (12%) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7months, and median overall survival (OS) was 14.3 and 10.5months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n=19, OS of 20.4months), taxanes (n=55, OS of 20.2months), gemcitabine (n=106, OS of 14.1months), topotecan (n=43, OS of 13months), and cyclophosphamide (n=21, OS of 13months). There was no significant difference in toxicities between the C+Bev vs. Bev alone group.
  
  
  CONCLUSIONS
  This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.
authors.affiliation: Division of Gynecologic Oncology, Helen Diller Family Comprehensive Cancer Center, University Of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1702, United States; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, School of Medicine, St. Louis, MO 63108, United States; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University, School of Medicine, 400 Pasteur Drive, Stanford, CA 94305, United States.
authors.forename: Katherine C
authors.initials: KC
authors.lastname: Fuh
authors.affiliation: Division of Gynecologic Oncology, Department Of Obstetrics and Gynecology, Duke University, School Of Medicine, DUMC 3079, Durham, NC 27710, United States.
authors.forename: Angeles A
authors.initials: AA
authors.lastname: Secord
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 1700 6th Ave South, Birmingham, AL 35233, United States.
authors.forename: Kerri S
authors.initials: KS
authors.lastname: Bevis
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 1700 6th Ave South, Birmingham, AL 35233, United States.
authors.forename: Warner
authors.initials: W
authors.lastname: Huh
authors.affiliation: The West Clinic, University of Tennessee, 100N. Humphreys Blvd, Memphis, TN 38120, United States.
authors.forename: Adam
authors.initials: A
authors.lastname: ElNaggar
authors.affiliation: Division of Gynecologic Oncology, Helen Diller Family Comprehensive Cancer Center, University Of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1702, United States; Palo Alto Medical Foundation Research Institute, 795 El Camino Real, Ames Building, Palo Alto, CA 94301, United States.
authors.forename: Kevin
authors.initials: K
authors.lastname: Blansit
authors.affiliation: Division of Gynecologic Oncology, Department Of Obstetrics and Gynecology, Duke University, School Of Medicine, DUMC 3079, Durham, NC 27710, United States.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Previs
authors.affiliation: The West Clinic, University of Tennessee, 100N. Humphreys Blvd, Memphis, TN 38120, United States.
authors.forename: Todd
authors.initials: T
authors.lastname: Tillmanns
authors.affiliation: Department of Radiation Oncology, Department of Obstetrics and Gynecology, Stanford University, School of Medicine, 400 Pasteur Drive, Stanford, CA 94305, United States.
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Kapp
authors.affiliation: Division of Gynecologic Oncology, Helen Diller Family Comprehensive Cancer Center, University Of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1702, United States; Palo Alto Medical Foundation Research Institute, 795 El Camino Real, Ames Building, Palo Alto, CA 94301, United States. Electronic address: chanjohn@sutterhealth.org.
authors.forename: John K
authors.initials: JK
authors.lastname: Chan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000188:drug therapy*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011859:Radiography; D066066:Response Evaluation Criteria in Solid Tumors; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D019772:Topotecan / Q000008:administration & dosage; D055815:Young Adult; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; C506643:liposomal doxorubicin; D003841:Deoxycytidine; D000068258:Bevacizumab; D011092:Polyethylene Glycols; D019772:Topotecan; D004317:Doxorubicin; D003520:Cyclophosphamide; D000093542:Gemcitabine
keywords: Bevacizumab; Chemotherapy; Liposomal doxorubicin, taxanes; Platinum-resistant; Recurrent epithelial ovarian cancer; Survival